Alberto Zambelli

8.5k total citations · 1 hit paper
172 papers, 4.2k citations indexed

About

Alberto Zambelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Alberto Zambelli has authored 172 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 47 papers in Cancer Research. Recurrent topics in Alberto Zambelli's work include Breast Cancer Treatment Studies (35 papers), Advanced Breast Cancer Therapies (28 papers) and HER2/EGFR in Cancer Research (23 papers). Alberto Zambelli is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), Advanced Breast Cancer Therapies (28 papers) and HER2/EGFR in Cancer Research (23 papers). Alberto Zambelli collaborates with scholars based in Italy, United States and France. Alberto Zambelli's co-authors include G. Lupinacci, Angela Amato, Laura Villani, Vincenzo Eterno, Sergio Brunati, Paolo Pedrazzoli, Luisa Ponchio, Paolo Giorgio Arcidiacono, L. La Mantia and Maurizio D’Incalci and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alberto Zambelli

162 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study

1988 685 citations Emilio Brocchi, G. Caletti et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alberto Zambelli Italy	33	1.6k	1.2k	932	823	761	172	4.2k
Luca Di Tommaso Italy	38	1.6k 1.0×	1.2k 1.0×	916 1.0×	1.2k 1.4×	1.5k 2.0×	162	4.7k
Ferry A.L.M. Eskens Netherlands	43	2.9k 1.8×	2.6k 2.2×	592 0.6×	515 0.6×	694 0.9×	161	6.4k
Yuan Ji China	41	2.0k 1.3×	1.6k 1.3×	1.5k 1.6×	1.1k 1.3×	1.5k 2.0×	244	5.9k
Alexander Laird United States	32	1.7k 1.1×	2.7k 2.3×	480 0.5×	343 0.4×	743 1.0×	97	4.9k
Carolyn D. Britten United States	36	3.0k 1.9×	2.4k 2.1×	935 1.0×	355 0.4×	417 0.5×	96	5.6k
Aiwu Ruth He United States	32	2.2k 1.4×	1.5k 1.3×	594 0.6×	609 0.7×	1.4k 1.9×	187	4.5k
Amit Mahipal United States	34	2.6k 1.6×	1.3k 1.1×	1.6k 1.7×	510 0.6×	364 0.5×	266	4.4k
John F. Gibbs United States	39	2.1k 1.3×	705 0.6×	1.9k 2.1×	829 1.0×	521 0.7×	150	4.7k
Arief A. Suriawinata United States	38	3.2k 2.1×	969 0.8×	2.4k 2.6×	1.1k 1.4×	578 0.8×	123	5.9k
Aaron Pollett Canada	33	3.9k 2.5×	2.6k 2.2×	710 0.8×	1.0k 1.2×	685 0.9×	87	6.8k

Countries citing papers authored by Alberto Zambelli

Since Specialization

Citations

This map shows the geographic impact of Alberto Zambelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Zambelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Zambelli more than expected).

Fields of papers citing papers by Alberto Zambelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Zambelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Zambelli. The network helps show where Alberto Zambelli may publish in the future.

Co-authorship network of co-authors of Alberto Zambelli

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Zambelli. A scholar is included among the top collaborators of Alberto Zambelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Zambelli. Alberto Zambelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conforti, Fabio, et al.. (2025). Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses. Cancers. 17(7). 1054–1054. 5 indexed citations

Gelardi, Fabrizia, Paola Tiberio, Flavia Jacobs, et al.. (2025). [18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?. La radiologia medica.

Tiberio, Paola, Rita De Sanctis, Arianna Magon, et al.. (2024). Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 204. 104527–104527.

Gerosa, Riccardo, Rita De Sanctis, Flavia Jacobs, et al.. (2024). Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Critical Reviews in Oncology/Hematology. 196. 104324–104324. 34 indexed citations

Tiberio, Paola, Matteo Castaldo, Alessandro Viganò, et al.. (2024). Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial). Journal of Personalized Medicine. 14(7). 711–711. 2 indexed citations

Sanctis, Rita De, Chiara Pozzi, Lidija Antunovic, et al.. (2024). Integrative predictive machine-learning based modelling for pathological complete response to neoadjuvant chemotherapy in breast cancer: A comprehensive analysis of breast microbiota, imaging, and clinical features. European Journal of Cancer. 200. 113652–113652. 1 indexed citations

Tiberio, Paola, Matteo Castaldo, Alessandro Viganò, et al.. (2024). Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care. Cancers. 16(16). 2806–2806. 1 indexed citations

Zambelli, Alberto, et al.. (2023). Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence. Critical Reviews in Oncology/Hematology. 191. 104104–104104. 2 indexed citations

Benvenuti, C., Paola Tiberio, Flavia Jacobs, et al.. (2023). Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave. Cancers. 15(5). 1410–1410. 10 indexed citations

10.

Fabi, Alessandra, Matteo Allegretti, G. Ferretti, et al.. (2023). Abstract OT1-22-01: Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients. Cancer Research. 83(5_Supplement). OT1–22. 1 indexed citations

11.

Jacobs, Flavia, et al.. (2023). Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. Cancers. 15(11). 2933–2933. 15 indexed citations

12.

Vernieri, Claudio, Francesca Ligorio, Claudia De Angelis, et al.. (2023). 352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial. Annals of Oncology. 34. S322–S323. 2 indexed citations

13.

Passardi, Alessandro, Flavia Foca, Orazio Caffo, et al.. (2022). A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial. Journal of Medical Internet Research. 24(1). e27349–e27349. 4 indexed citations

14.

Miglietta, Federica, Michela Cinquini, Maria Vittoria Dieci, et al.. (2022). PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. The Breast. 66. 293–304. 7 indexed citations

15.

Vitali, Francesca, Laurie D. Cohen, Angela Amato, et al.. (2016). A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer. PLoS ONE. 11(9). e0162407–e0162407. 55 indexed citations

16.

Kloth, Jacqueline S. L., Alessia Pagani, Alberto Malovini, et al.. (2015). Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. British Journal of Cancer. 112(6). 1011–1016. 71 indexed citations

17.

Marchini, Sergio, Robert Fruscio, Luca Clivio, et al.. (2012). Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. European Journal of Cancer. 49(2). 520–530. 146 indexed citations

18.

Barkholt, Lisbeth, Marco Bregni, Mats Remberger, et al.. (2006). Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology. 17(7). 1134–1140. 58 indexed citations

19.

Gennari, Roberto, Sylvie Ménard, Francesco Fagnoni, et al.. (2004). Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer Research. 10(17). 5650–5655. 382 indexed citations

20.

Brocchi, Emilio, G. Caletti, G. Brambilla, et al.. (1988). Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. New England Journal of Medicine. 319(15). 983–989. 685 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact